Results 61 to 70 of about 12,783,707 (261)

A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer [PDF]

open access: yes, 2001
BACKGROUND: The incidence of lung cancer is declining following a drop in smoking rates, but it is still the leading cause of death from cancer in England and Wales, with about 30,000 deaths a year.
A. Clegg   +14 more
core   +1 more source

Analysis of Efficacy and Safety of Neoadjuvant Immunochemotherapy in Patients
with Stage IB-IIIB Non-small Cell Lung Cancer

open access: yesChinese Journal of Lung Cancer
Background and objective Neoadjuvant immunochemotherapy has emerged as an indispensable therapeutic modality for non-small cell lung cancer (NSCLC).
Zihao LI   +7 more
doaj   +1 more source

Loss of IGF‐1R impairs DNA‐PKcs recruitment to chromatin leading to defective end‐joining

open access: yesMolecular Oncology, EarlyView.
IGF‐1R promotes radioresistance by facilitating DNA‐PKcs recruitment to chromatin, enabling non‐homologous end‐joining (NHEJ) repair of double‐strand breaks. Inhibition or loss of IGF‐1R disrupts this recruitment to damage sites, driving compensatory reliance on microhomology‐mediated end‐joining (MMEJ) repair.
Matthew O. Ellis   +3 more
wiley   +1 more source

Long noncoding nature brain-derived neurotrophic factor antisense is associated with poor prognosis and functional regulation in non–small cell lung caner

open access: yesTumor Biology, 2017
In this study, we evaluated the prognostic potential and functional regulation of human nature antisense, brain-derived neurotrophic factor antisense, in non–small cell lung cancer.
MingJing Shen   +5 more
doaj   +1 more source

Caucasian validation of downstaging from IIB to IIA in T1N1M0 patients within the 9th edition of the non‐small cell lung cancer tumor‐node‐metastasis staging

open access: yesCancer Medicine
Background The 9th edition of the lung cancer tumor‐node‐metastasis (TNM) staging introduced adjustments, including the reclassification of T1N1M0 patients from stage IIB to IIA. This update used data mostly from Asian populations.
Jingsheng Cai, Yun Li, Feng Yang
doaj   +1 more source

Clinicopathological and molecular features of non-small cell lung cancer that transform to small-cell lung cancer: Case reports and literature review

open access: yesPolish Journal of Pathology
The purpose of this study is to explore the clinical and pathological characteristics as well as the molecular pathogenesis of patients with non-small cell lung cancer (NSCLC) transforming into small cell lung cancer (SCLC). We investigated 14 patients
Qiqi Gao, Lixin Zhang, Yulong Zheng
doaj   +1 more source

Small-cell lung cancer

open access: yesМедицинский вестник Юга России, 2017
Lung cancer – one of the most common malignancies in the world. Currently, domestic publications addressing issues of classifi cation, clinic, diagnosis, treatment, a form of lung cancer - non-small cell cancer, is extremely small.
Nicolay G. Bakhmutsky   +3 more
doaj   +1 more source

Flow Enabled Target Capture Halbach‐based magnetic enrichment increases circulating tumor cell capture from blood in metastatic cancer patients

open access: yesMolecular Oncology, EarlyView.
Pair‐wise comparison of the CellSearch and FETCH enrichment technologies for circulating tumor cells (CTCs) from metastatic breast, prostate, and small cell lung cancer patients shows an increased capture of CTCs using FETCH enrichment. The clinical implementation of circulating tumor cells (CTCs) as a predictive tool for therapy efficacy in the ...
Michiel Stevens   +6 more
wiley   +1 more source

Characterisation and modulation of drug resistance in lung cancer cell lines [PDF]

open access: yes, 2010
Chemotherapy drug resistance is a major obstacle in the treatment of cancer. It can result from an increase in levels of cellular drug efflux pumps such as P-glycoprotein (P-gp).
Dunne, Gráinne
core   +2 more sources

MITF maintains genome stability in nonmelanocyte lineages

open access: yesMolecular Oncology, EarlyView.
MITF is essential for melanocyte survival and acts as an oncogene in 10%–20% of melanomas. We show that MITF depletion causes genome instability in nonmelanocytic cells, leading to LATS2‐mediated P53 activation, cell cycle arrest, and apoptosis. This study highlights the role of MITF as a genome maintenance factor beyond the melanocyte lineage. Created
Drifa H. Gudmundsdottir   +13 more
wiley   +1 more source

Home - About - Disclaimer - Privacy